Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 27 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| XTL BIOPHARMACEUTICALS LTD | 57,092,850 | reported | 04 Jun 2008 | tx 56+8,925,610 |
| AMICUS THERAPEUTICS, INC. | 20,674,424 | reported | 21 Sept 2018 | tx 18+7,326,375 |
| Quotient Ltd | 16,200,818 | reported | 15 Sept 2020 | tx 5+5,667,798−2,306,034 |
| AGILE THERAPEUTICS INC | 14,919,925 | reported | 25 Feb 2020 | tx 5+4,400,000−1,058,919 |
| ADMA BIOLOGICS, INC. | 14,802,978 | reported | 19 Aug 2021 | tx 3−1,781,824 |
| Athenex, Inc. | 11,532,467 | reported | 24 Dec 2019 | tx 6+253,698 |
| MeiraGTx Holdings plc | 10,231,103 | reported | 31 Dec 2025 | tx 7+7,065,507−2,300,000 |
| Solid Biosciences Inc. | 8,912,655 | reported | 09 Mar 2026 | tx 2+8,922,305 |
| CYPHERPUNK TECHNOLOGIES INC. | 8,476,496 | reported | 22 Jun 2020 | tx 1+1,750,000 |
| ARYA Sciences Acquisition Corp II | 6,511,727 | reported | 16 Aug 2022 | tx 4+4,625,000 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 09 Mar 2026 | GRANT_AWARD | Solid Biosciences Inc. | 8,912,655 | 5.61 USD | deriv |
| 31 Dec 2025 | OTHER | MeiraGTx Holdings plc | 2,300,000 | 7.91 USD | |
| 01 Aug 2025 | PURCHASE | Orchestra BioMed Holdings, Inc. | 700,000 | 2.75 USD | first after silence |
| 01 Aug 2025 | PURCHASE | Orchestra BioMed Holdings, Inc. | 1,500,000 | 2.75 USD | deriv |
| 03 Apr 2025 | SALE | Aldeyra Therapeutics, Inc. | 3,400,000 | 1.42 USD | |
| 11 Apr 2024 | PURCHASE | Acrivon Therapeutics, Inc. | 2,353,000 | 8.50 USD | |
| 03 Apr 2024 | PURCHASE | Aldeyra Therapeutics, Inc. | 309,847 | 4.09 USD | |
| 01 Apr 2024 | PURCHASE | Aldeyra Therapeutics, Inc. | 8,374 | 3.25 USD | |
| 02 Apr 2024 | PURCHASE | Aldeyra Therapeutics, Inc. | 186,051 | 3.44 USD | |
| 15 Feb 2024 | EXERCISE | LianBio | 36,300 | 2.52 USD | |
| 15 Feb 2024 | EXERCISE | LianBio | 36,300 | 2.52 USD | |
| 15 Feb 2024 | TAX_WITHHOLDING | LianBio | 19,218 | 4.76 USD | |
| 15 Feb 2024 | TAX_WITHHOLDING | LianBio | 19,218 | 4.76 USD | |
| 15 Feb 2024 | EXERCISE | LianBio | 36,300 | 0.00 USD | deriv |
| 15 Feb 2024 | EXERCISE | LianBio | 36,300 | 0.00 USD | deriv |
| 16 Oct 2023 | PURCHASE | Astria Therapeutics, Inc. | 614,062 | 6.51 USD | |
| 16 Oct 2023 | PURCHASE | Astria Therapeutics, Inc. | 460,546 | 6.51 USD | |
| 16 Oct 2023 | PURCHASE | Astria Therapeutics, Inc. | 460,546 | 6.51 USD | deriv |
| 16 Oct 2023 | PURCHASE | Astria Therapeutics, Inc. | 921,093 | 6.51 USD | deriv |
| 16 Oct 2023 | PURCHASE | Astria Therapeutics, Inc. | 921,093 | 6.51 USD | deriv |
| 16 Oct 2023 | PURCHASE | Astria Therapeutics, Inc. | 614,062 | 6.51 USD | deriv |
| 18 Oct 2023 | SALE | Aldeyra Therapeutics, Inc. | 306,499 | 1.74 USD | |
| 16 Oct 2023 | SALE | Aldeyra Therapeutics, Inc. | 2,450,000 | 1.60 USD | |
| 15 Jun 2023 | GRANT_AWARD | Nautilus Biotechnology, Inc. | 45,000 | 0.00 USD | deriv |
| 30 May 2023 | PURCHASE | SOLENO THERAPEUTICS INC | 17,500 | 5.34 USD |
4 purchases reported after at least 12 months of silence — most recent on 01 Aug 2025.